Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neutropenia × Anidulafungin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Invasive Fungal Infections 1 Infections 1 Hematologic Neoplasms 1 Carcinoma, Hepatocellular 1 Candidiasis, Invasive 1

Interventions

pegfilgrastim 30 Filgrastim 27 Cyclophosphamide 10 Docetaxel 8 pegylated granulocyte colony-stimulating factor 7 Etoposide 7 Cytarabine 7 Leucovorin 5 Fluorouracil 5 Ciprofloxacin 5 Cefepime 5 eflapegrastim 4 Vancomycin 4 Granulocyte Colony-Stimulating Factor 4 Doxorubicin 4 Peripheral Blood Stem Cell Transplantation 3 Mitoxantrone 3 Methotrexate 3 Irinotecan 3 Idarubicin 3 Daunorubicin 3 Cyclosporine 3 Carboplatin 3 plerixafor 2 Vincristine 2 Topotecan 2 Thioguanine 2 Radiotherapy 2 Piperacillin, Tazobactam Drug Combination 2 Oxaliplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00068471 2013-06-19

Anidulafungin in Treating Immunocompromised Children With Neutropenia

National Cancer Institute (NCI)

Phase 1/2 Completed

Infections, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡